Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 1/20 | 0.46 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | MYC | P01106 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 2/20 | 0.36 |
| ▸ | NOS2 | P35228 | 2/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.35 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31281693 | 0.82 | P4HA1 (0.55) | KCNQ3KCNQ2NAPRTGRM5P4HA1 | |
| SCHEMBL65165 | 0.82 | P4HA1 (0.55) | KCNQ3KCNQ2NAPRTGRM5P4HA1 | |
| SCHEMBL1993840 | 0.81 | GRM5 (0.58) | KCNQ3KCNQ2GRM5MYC | |
| SCHEMBL1584376 | 0.81 | MAPT (0.49) | KCNQ3KCNQ2S1PR1S1PR3AR | |
| SCHEMBL2515153 | 0.81 | KCNQ3 (0.46) | KCNQ3KCNQ2S1PR1S1PR3AR | |
| SCHEMBL19580190 | 0.81 | KCNQ3 (0.46) | KCNQ3KCNQ2S1PR1S1PR3AR | |
| SCHEMBL12160256 | 0.77 | GSK3B (0.56) | KCNQ3KCNQ2S1PR1S1PR3AR | |
| SCHEMBL880697 | 0.77 | MAPK1 (0.59) | KCNQ3KCNQ2ARPTPN1NOS1 | |
| SCHEMBL3820613 | 0.77 | GRM5 (0.61) | KCNQ3KCNQ2S1PR1S1PR3AR | |
| SCHEMBL22583293 | 0.77 | ALDH1A1 (0.46) | KCNQ3KCNQ2S1PR1S1PR3AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114507181-B | Propionic acid compound containing 5-substituted tetrahydroisoquinoline, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2024-03-26 | — | — | CN | disclosed |
| CN-113149900-B | Amide compound and application thereof | 沈阳化工大学 | 2023-09-15 | — | — | CN | disclosed |
| US-20220220073-A1 | BISAMIDE COMPOUND AND APPLICATION THEREOF | Metisa Biotechnology Co., Ltd (CN) | 2022-07-14 | — | — | US | disclosed |
| CN-114507181-A | Propionic acid compound containing 5-substituted tetrahydroisoquinoline, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2022-05-17 | — | — | CN | disclosed |
| WO-2021139370-A1 | AMIDE COMPOUND AND APPLICATION THEREOF | 沈阳化工大学 | 2021-07-15 | — | — | WO | disclosed |
| WO-2021139370-A1 | AMIDE COMPOUND AND APPLICATION THEREOF | 沈阳化工大学 | 2021-07-15 | — | — | WO | disclosed |
| EP-2736907-B1 | INDAZOLES | PFIZER LTD (GB) | 2015-10-07 | — | — | EP | disclosed |
| US-8895544-B2 | Indazoles | PFIZER LIMITED (GB) | 2014-11-25 | — | — | US | disclosed |
| EP-2736907-A1 | INDAZOLES | Pfizer Limited (GB) | 2014-06-04 | — | — | EP | disclosed |
| US-20140024634-A1 | INDAZOLES | PFIZER LIMITED (GB) | 2014-01-23 | — | — | US | disclosed |
| US-7393859-B2 | Amide substituted imidazoquinolines | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| EP-1187613-B9 | AMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2006-10-25 | — | — | EP | disclosed |
| EP-1187613-B1 | AMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20040229897-A1 | Amide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-11-18 | — | — | US | disclosed |
| US-6756382-B2 | SECONDARY AMIDES SUCH AS N-(4-(4-AMINO-2-(2-METHOXYETHYL)-1H-IMIDAZO(4,5-C)QUINOLIN-1-YL)BUTYL)-1 -METHYL-5-OXO-2-PYRIDIN-3-YLPYRROLIDINE-3-CARBOXAMIDE; BIOSYNTHESIS OF CYTOKINES; PROPYLAXIS OF VIRAL DISEASES; IMMUNOLOGY MODULATORS | 3M INNOVATIVE PROPERTIES COMPANY | 2004-06-29 | — | — | US | disclosed |
| US-20030144283-A1 | Amide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-07-31 | — | — | US | disclosed |
| US-6451810-B1 | AID IN CYTOKINE BIOSYNTHESIS | 3M INNOVATIVE PROPERTIES COMPANY | 2002-09-17 | — | — | US | disclosed |
| EP-1187613-A4 | AMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2002-07-24 | — | — | EP | disclosed |
| EP-1187613-A1 | AMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2002-03-20 | — | — | EP | disclosed |
| WO-2000076505-A1 | AMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229897-A1 | Amide substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | KCNQ3 2190/4885KCNQ2 1967/4885S1PR1 3856/4885 |
| US-20140024634-A1 | INDAZOLES | JAK1, JAK3, JAK2 | KCNQ3 787/4885KCNQ2 1191/4885S1PR1 1451/4885 |
| US-20030144283-A1 | Amide substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | KCNQ3 2190/4885KCNQ2 1967/4885S1PR1 3856/4885 |
| US-20220220073-A1 | BISAMIDE COMPOUND AND APPLICATION THEREOF | FHIT, DDT, BCHE | KCNQ3 1649/4885KCNQ2 872/4885S1PR1 4070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.